ClinicalTrials.gg
Active, not recruitingNCT04548999GAVOTTEUpdated Jul 24, 2026Results posted

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)

A Phase 3 interventional study of Ocrelizumab and Ocrelizumab in Multiple Sclerosis, sponsored by Hoffmann-La Roche. Active, not recruiting at 147 sites in 22 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-07-24.

Primary conditionMultiple Sclerosis, Chronic ProgressiveRegistry: Multiple SclerosisReclassifiedWhy we changed it
Registry
Multiple Sclerosis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Multiple Sclerosis, Chronic Progressive
Why
  1. The study's title name Multiple Sclerosis, Chronic Progressive, a narrower term within Multiple Sclerosis.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
769
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing ocrelizumab in Multiple Sclerosis, Chronic Progressive — 2 open to participants now, 6 under way, 4 of them phase 3. ocrelizumab · Multiple Sclerosis, Chronic Progressive.

Enrollment
3rd of 10
769 · median 184
Started
2020
the only one that year
Phase 3
7 of 10
1 open now
Registered
6th of 10
by date
Lead sponsor
6 of 10
Hoffmann-La Roche

Among the 10 studies testing ocrelizumab in Multiple Sclerosis, Chronic Progressive, this one is the 3rd largest by enrollment, is the only one that started in 2020, is one of 7 in phase 3, and was the 6th registered.

Multiple Sclerosis, Chronic Progressive

245 studies on the registry are indexed under Multiple Sclerosis, Chronic Progressive; 54 are open to participants now.

Browse Multiple Sclerosis, Chronic Progressive studies →

Open to participants now

2 of the 10 studies testing ocrelizumab in Multiple Sclerosis, Chronic Progressive are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About ocrelizumab

ocrelizumab: first FDA approval 2017 (OCREVUS), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 39 Multiple Sclerosis, Chronic Progressive studies recruiting now, 7 (18%) set no upper age limit and 26 (67%) stop at 75 or younger; none take children under 18; 6 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing ocrelizumab in Multiple Sclerosis, Chronic Progressive, or all of them as a file.
02

Study summary

This is a randomized, double blind, controlled, parallel group, multicenter study to evaluate efficacy, safety and PK of a higher dose of ocrelizumab per intravenous (IV) infusion every 24 weeks (Q24W) in participants with PPMS, in comparison to the approved 600 milligrams (mg) dose of ocrelizumab.

Read the detailed description

Participants will be treated for a minimum of 120 weeks in the double-blind treatment (DBT) phase. Upon positive primary results after the DBT phase, an optional higher dose extension treatment, open-label extension (OLE) phase is planned for eligible participants. The OLE will be carried out for approximately 96 weeks. Participants will be followed for safety for 48 weeks thereafter. Participants whose B-cell levels still did not replete to their baseline level or the lower limit of normal (LLN), whichever is lower, will move into the B-cell monitoring (BCM) phase following the safety follow-up phase. The study will end when all participants who were not treated with an alternative B-cell depleting therapy have repleted their B-cells to the baseline value or the LLN.

03

Conditions studied

  • Multiple Sclerosis

Browse trials for

Keywords

  • Primary Progressive Multiple Sclerosis; Higher Dose of CD20 Antibody Ocrelizumab; Efficacy, Safety and Pharmacokinetics
04

In context

Multiple Sclerosis, Chronic Progressive Reclassified

245 studies on the registry are indexed under Multiple Sclerosis, Chronic Progressive; 54 are open to participants now.

This study's enrollment of 769 is above the median of 54 across 190 interventional studies indexed under Multiple Sclerosis, Chronic Progressive.

Browse Multiple Sclerosis, Chronic Progressive studies →

Lead sponsor

Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.

Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.

Compared within Multiple Sclerosis, Chronic Progressive, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Multiple Sclerosis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of PPMS
  • EDSS score at screening and baseline, from 3 to 6.5 inclusive
  • Average T25FWT score over two trials at screening and over two trials at baseline respectively, up to 150 (inclusive) seconds
  • Average 9HPT score over four trials (two trials with each hand) at screening and over four trials (two trials with each hand) at baseline respectively, up to 250 (inclusive) seconds
  • Score of ≥ to 2.0 on the Functional Systems (FS) scale for the pyramidal system that was due to lower extremity findings at screening and baseline
  • Documented magnetic resonance imaging (MRI) of brain with abnormalities consistent with MS
  • Participants requiring symptomatic treatment for MS and/or physiotherapy must be treated at a stable dose. No initiation of symptomatic treatment for MS or physiotherapy within 4 weeks of randomization
  • Participants must be neurologically stable for at least 30 days prior to randomization and baseline
  • Disease duration from the onset of MS symptoms; if EDSS score at screening is ≤ 5, disease duration must be less than 10 years; If EDSS score at screening is > 5, disease duration must be less than 15 years
  • Documented evidence of the presence of at least one cerebrospinal fluid-specific oligoclonal bands
  • Females of : agreement to remain abstinent or use adequate methods
  • Female participants, without may be enrolled e.g. if or if surgically sterile

Exclusion criteria

Exclusion Criteria:

  • History of relapsing remitting or secondary progressive MS at screening
  • Any known or suspected active infection at screening or baseline (except nailbed infections), or any major episode of infection requiring hospitalization or treatment with IV antimicrobials within 8 weeks or treatment with oral antimicrobials within 2 weeks, prior to and during screening
  • History of confirmed or suspected progressive multifocal leukoencephalopathy
  • History of cancer, including hematologic and solid tumors, within 10 years of screening
  • state
  • Receipt of a live or within 6 weeks prior to randomization
  • Inability to complete an MRI or to gadolinium administration
  • Contraindications to mandatory pre-medications for infusion-related reaction (IRRs)
  • Known presence of other neurologic disorders that could interfere with the diagnosis of MS or assessments of efficacy and/or safety during the study
  • Any concomitant disease that may require chronic treatment with systemic or immunosuppressants during the course of the study
  • Significant, uncontrolled disease that may preclude participant from participating in the study
  • History of or currently active primary or secondary, non-drug-related, immunodeficiency
  • Pregnant or breastfeeding or intending to become pregnant
  • Lack of peripheral venous access
  • History of alcohol or other drug abuse within 12 months prior to screening
  • Treatment with any agent or treatment with any experimental procedure for MS
  • Previous use of anti-cluster of differentiation 20 (CD20s) (including ocrelizumab), unless the last infusion was more than 2 years before screening, B-cell count is normal, and the stop of the treatment was not motivated by safety reasons or lack of efficacy
  • Any previous treatment with mitoxantrone, cladribine, atacicept, alemtuzumab, and daclizumab
  • Previous treatment with fingolimod, siponimod, or ozanimod within 6 weeks of baseline
  • Previous treatment with natalizumab within 4.5 months of baseline
  • Previous treatment with interferons beta (1a or 1b), or glatiramer acetate within 2 weeks of baseline
  • Previous treatment with any other immunomodulatory or immunosuppressive medication not already listed above without appropriate as described in the applicable local label. If the washout requirements are not described in the applicable local label, then the wash out period must be five times the half-life of the medication
  • Any previous treatment with bone marrow transplantation and hematopoietic stem cell transplantation
  • Any previous history of transplantation or anti-rejection therapy
  • Treatment with IV immunoglobulin (Ig) or plasmapheresis within 12 weeks prior to randomization
  • Systemic corticosteroid therapy within 4 weeks prior to screening
  • Positive screening tests for active, latent, or inadequately treated
  • Sensitivity or intolerance to any ingredient (including ) of ocrelizumab
  • Any additional exclusionary criterion as per ocrelizumab local label, if more stringent than the above
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
769 participants (actual)

Study arms

  • Experimental
    Ocrelizumab Higher Dose

    Participants will be randomized to receive a minimum of 5 higher treatment doses based on their body weight at baseline: 1200 mg (participant's body weight \<75 kilograms \[kg\]) or 1800 mg (participant's body weight ≥ 75 kg) of ocrelizumab administered by IV infusion Q24W in the DBT phase. During the optional OLE phase, participants will continue with their assigned dose of ocrelizumab (either 1200 or 1800 mg) for approximately 96 weeks (4 doses in total). Mandatory methylprednisolone (or equivalent) and antihistaminic drug (e.g., diphenhydramine or equivalent) will be administered approximately 30-60 minutes prior to the start of each ocrelizumab infusion.

    Drug: Ocrelizumab · Drug: Antihistamine · Drug: Methylprednisolone

  • Active comparator
    Ocrelizumab Approved Dose

    Participants will be randomized to receive a minimum of 5 treatment doses of 600 mg ocrelizumab administered by IV infusion Q24W in the DBT phase. During the optional OLE phase, participants will be offered a higher dose of ocrelizumab (either 1200 or 1800 mg), based on their body weight at OLE baseline, for approximately 96 weeks (4 doses in total). Mandatory methylprednisolone (or equivalent) and antihistaminic drug (e.g., diphenhydramine or equivalent) will be administered approximately 30-60 minutes prior to the start of each ocrelizumab infusion.

    Drug: Ocrelizumab · Drug: Antihistamine · Drug: Methylprednisolone

Interventions

  • The actual higher dose of ocrelizumab will be assigned to participants based on their body weight at baseline: 1200 mg (body weight \<75 kg) or 1800 mg (body weight ≥ 75 kg). The first dose of ocrelizumab will be administered as two 600 mg or 900 mg IV infusions given 14 days apart. For the subsequent doses, ocrelizumab will be administered as a single 1200 mg or 1800 mg IV infusion Q24W. During the optional OLE phase, participants will continue with their assigned dose of ocrelizumab (either 1200 or 1800 mg) for approximately 96 weeks (4 doses in total)

    Also known as: Ocrevus

  • Ocrelizumab will be administered at a dose of 600 mg Q24W. The first dose of ocrelizumab will be administered as two 300 mg, IV infusions given 14 days apart. For the subsequent doses, ocrelizumab will be administered as a single 600 mg IV infusion Q24W.

    Also known as: Ocrevus

  • Premedication with oral or IV antihistaminic drug (i.e., diphenhydramine 50 mg or an equivalent dose of an alternative) will be administered prior to each ocrelizumab infusion.

    Also known as: Non-Investigational Medicinal Product

  • Premedication with 100 mg of methylprednisolone (or equivalent) will be administered by IV infusion prior to each ocrelizumab infusion.

    Also known as: Non-Investigational Medicinal Product

07

What researchers measure

Primary outcomes

  1. Time to Onset of 12-week Composite Confirmed Disability Progression (cCDP12)

    Time to onset of 12-week cCDP=first occurrence of a 12-week cCDP according to at least 1 of the 3 criteria: 1) CDP=12-week confirmed increase (CI) from baseline (FB) in expanded disability status scale (EDSS) score of ≥1.0 point in participants with baseline EDSS score of ≤5.5 or 12-week CI≥0.5 point in participants with baseline EDSS score of \>5.5 OR 2) 12-week CI of ≥20% FB in Timed 25-foot Walk Test (T25FWT) score OR 3)12-week CI of ≥ 20% FB in 9-hole Peg Test (9-HPT) score. EDSS = disability scale that ranges in 0.5-point steps from 0 \[normal\]-10.0 \[death\]. In T25FWT test participants walked to a 25 foot course as quickly \& safely as possible. Score = average of 2 completed trials (in seconds). In 9-HPT, participants had to place \& remove pegs 1 by 1 into 9 holes arranged in a board \& complete 2 successful trials for each hand \& the amount of time (in seconds) required was recorded. In T25FWT \& 9-HPT the longer it took complete test= higher scores, indicating deterioration.

    Time frame: Up to approximately 4.5 years

Secondary outcomes

  1. Time to Onset of 24-week cCDP (cCDP24)

    Time to onset of a 24 week cCDP=first occurrence of a 24-week cCDP according to at least 1 of 3 criteria: 1) CDP=24-week CI from baseline in EDSS score of ≥1.0 point in participants with baseline EDSS score of ≤5.5 or 24-week CI≥0.5 point in participants with baseline EDSS score of \>5.5 OR 2) 24-week CI of ≥20% FB in T25FWT score OR 3) 24-week CI of ≥ 20% FB in 9-HPT score. EDSS = disability scale that ranges in 0.5-point steps from 0 \[normal\]-10.0 \[death\]. In T25FWT test participants walked to a 25 foot course as quickly \& safely as possible. Score = average of 2 completed trials (in seconds). In 9-HPT, participants had to place \& remove pegs 1 by 1 into 9 holes arranged in a board \& complete 2 successful trials for each hand \& the amount of time (in seconds) required was recorded. In T25FWT \& 9-HPT the longer it took complete test= higher scores, indicating deterioration.

    Time frame: Up to approximately 4.5 years

  2. Time to Onset of cCDP12 Independent of Protocol-defined Relapses (PDR) or Progression Independent of Relapse Activity (PIRA)

    Time to onset of 12-week cCDP=first occurrence of a 12-week cCDP according to at least 1 of 3 criteria: 1) CDP=12-week CI from baseline in EDSS score of ≥1.0 point in participants with baseline EDSS score of ≤5.5 or 12-week CI≥0.5 point in participants with baseline EDSS score of \>5.5 OR 2) 12-week CI of ≥20% FB in T25FWT score OR 3) 12-week CI of ≥ 20% FB in 9-HPT score. EDSS score, T25FWT \& 9-HPT are the same as defined in primary outcome measure. Protocol-defined relapse=occurrence of new or worsening neurological symptoms attributable to MS and immediately preceded by a relatively stable or improving neurological state of at least 30 days. Symptoms persist for at least 24 hours \& accompanied by objective neurological worsening consistent with an increase of one of the following: Half a step (0.5 point) on the EDSS; Two points on one of the functional system scores (FSS) (pyramidal, ambulation, cerebellar, brainstem, sensory, or visual); One point on ≥2 more of the FSS.

    Time frame: Up to approximately 4.5 years

  3. Time to Onset of 12-week Confirmed Disability Progression (CDP12)

    CDP was defined as a 12-week confirmed increase from baseline in EDSS score of ≥1.0 point in participants with a baseline EDSS score of ≤5.5 or a 12-week CI ≥0.5 points in participants with a baseline EDSS score of \>5.5. The EDSS was used to measure changes in the disability level of participants with MS over time. EDSS is based on a standard neurological examination, incorporating functional systems (visual, brainstem, pyramidal, cerebellar, sensory, bowel and bladder, and cerebral \[or mental\]) that are rated and then scored as a FSS, and ambulation, which is scored as ambulation score. Each FSS is an ordinal clinical rating scale where score range from 0 to 5 or 6, and ambulation score that is rated from 0 to 16. These ratings along with observations and assistive devices were then used to determine the total EDSS score. The total EDSS score ranges from 0 (normal) to 10.0 (death) in 0.5-point steps.

    Time frame: Up to approximately 4.5 years

  4. Time to ≥ 20% Increase in 12-week Confirmed T25FWT

    T25FWT test is a performance measure used to assess walking speed based on a timed 25-foot walk. The participant was directed to start at one end of a clearly marked 25-foot course and was instructed to walk 25 feet as quickly and safely as possible. The Examining Investigator timed the participants from the start of the walk to the end of the 25 feet. The task was immediately administered again by having the participant walk back the same distance. Participants could use assistive devices (e.g., cane, crutch, or rollator) when performing the task. Score was the average of the two completed trials, measured in seconds. The longer it takes to walk, higher the score, indicating deterioration. A 20% change from baseline of the averaged T25FWT was considered clinically meaningful.

    Time frame: Up to approximately 4.5 years

  5. Time to Onset of 12-week Confirmed ≥ 4-point Worsening in Symbol Digit Modalities Test (SDMT)

    The SDMT is a performance measure that demonstrated sensitivity in detecting the presence of cognitive impairment and changes in cognitive functioning over time \& in response to treatment. The SDMT presents a series of nine symbols, each paired with a single digit in a key at the top of a standard sheet of paper. Participants were asked to pair specific numbers with given geometric figures within 90 seconds. Responses were collected orally. The score is the number of correctly paired items in 90 seconds with a maximum score of 110 and minimum of 0. Higher scores indicate improvement. A four-point change from baseline was considered clinically meaningful.

    Time frame: Up to approximately 4.5 years

  6. Time to Onset of 24-week Confirmed ≥ 8-point Increase in 12-Item Multiple Sclerosis Walking Scale (MSWS-12)

    The MSWS-12 was a 12-item self-report measure of the impact of MS on the participant's ability to walk during the past 2 weeks. Each item was scored on a 5-point Likert scale ranging from 1 (not at all) to 5 (extremely likely). Scores were summed and linearly converted to a 0-100 scale with higher scores indicating greater impact of MS on walking ability. An 8-point change was considered clinically meaningful.

    Time frame: Up to approximately 4.5 years

  7. Annual Rate of Percent Change From Baseline in Total Brain Volume

    Brain volume was measured using magnetic resonance imaging (MRI) scans. Mean difference in annual rate of percent change from baseline in total brain volume between the higher and approved dose of ocrelizumab arms in participants with RMS where no treatment discontinuation nor initiation of alternative MS treatment occurred, are reported.

    Time frame: Up to approximately 4.5 years

  8. Annual Rate of Percent Change From Baseline in Thalamic Volume

    Thalamic volume was measured using MRI scans. Mean difference in annual rate of percent change from baseline in thalamic volume between the higher and approved dose of ocrelizumab arms in participants with RMS where no treatment discontinuation nor initiation of alternative MS treatment occurred, are reported.

    Time frame: Up to approximately 4.5 years

  9. Ratio of Fold Change From Baseline in Neurofilament Light Chain (NfL) Levels at Week 96

    NfL is a biomarker of neuroinflammation in CSF. Ratio of the mean change from baseline in NfL at Week 96 between the higher and approved dose of ocrelizumab arms in PPMS participants where no treatment discontinuation nor initiation of alternative MS treatment occurred have been reported. The results correspond to fold change from baseline (i.e., ratio of adjusted geometric means at Week 96 vs baseline).

    Time frame: At Week 96

  10. Fold Change From Baseline in NfL Levels at Week 96 Within the Higher Dose Ocrelizumab Group

    NfL is a biomarker of neuroinflammation in CSF. Mean change from baseline in NfL at Week 96 for PPMS participants where no treatment discontinuation nor initiation of alternative MS treatment occurred within the ocrelizumab higher dose group have been reported. The results correspond to fold change from baseline (i.e., ratio of adjusted geometric mean at Week 96 vs baseline).

    Time frame: At Week 96

  11. Fold Change From Baseline in NfL Levels at Week 96 Within the Approved Dose Ocrelizumab Group

    NfL is a biomarker of neuroinflammation in CSF. Mean change from baseline in NfL at Week 96 for PPMS participants where no treatment discontinuation nor initiation of alternative MS treatment occurred within the ocrelizumab 600 mg group have been reported. The results correspond to fold change from baseline (i.e., ratio of adjusted geometric mean at Week 96 vs baseline).

    Time frame: At Week 96

  12. Number of Participants With Adverse Events (AEs)

    AE was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

    Time frame: From initiation of study drug up to approximately 6.8 years

  13. Area Under the Serum Concentration-time Curve (AUC) of Ocrelizumab Over the First Dosing Interval

    Time frame: Day 1 to Week 24

  14. B-cell Levels in Blood

    Time frame: Baseline, Weeks 2, 24, 48, 72, 96, 120, 144, 168, 192 and 216

  15. Percent Change From Baseline in B-cell Levels

    Time frame: Weeks 2, 24, 48, 72, 96, 120, 144, 168, 192 and 216

  16. Percentage of Participants Who Achieved ≤ 5 B-cells/μL of Blood

    Time frame: Baseline, Weeks 2, 24, 48, 72, 96, 120, 144, 168, 192 and 216

  17. Percentage of Participants Who Achieved ≤ 0.4 B-cells/μL of Blood

    Time frame: Baseline, Weeks 2, 24, 48, 72, 96, 120, 144, 168, 192 and 216

  18. Percentage of Participants With Anti-drug Antibodies (ADAs) to Ocrelizumab

    Participants were considered to be ADA-positive if they were ADA-negative or had missing data at baseline but developed an ADA response following study drug exposure, or if they were ADA-positive at baseline and the titer of 1 or more post-baseline samples was at least 0.60 titer unit (t.u.) greater than the baseline titer result. Percentages have been rounded off.

    Time frame: Up to approximately 4.5 years

08

Results

Posted Jul 24, 2026

Participant flow

A total of 769 participants with primary progressive multiple sclerosis (PPMS) took part in the study at 149 investigative sites across 22 countries. The study is still ongoing.

Participant flow — Overall Study
MilestoneOcrelizumab 600 mgOcrelizumab 1200 mg or 1800 mg
Started253500
Safety analysis set (sas)254499
Completed00
Not completed253500
Withdrew: Adverse event24
Withdrew: Death23
Withdrew: Lost to follow-up13
Withdrew: Reason not specified01
Withdrew: Physician decision27
Withdrew: Withdrawal by subject1538
Withdrew: Ongoing in study231444

Outcome measures

PrimaryTime to Onset of 12-week Composite Confirmed Disability Progression (cCDP12)

Time to onset of 12-week cCDP=first occurrence of a 12-week cCDP according to at least 1 of the 3 criteria: 1) CDP=12-week confirmed increase (CI) from baseline (FB) in expanded disability status scale (EDSS) score of ≥1.0 point in participants with baseline EDSS score of ≤5.5 or 12-week CI≥0.5 point in participants with baseline EDSS score of \>5.5 OR 2) 12-week CI of ≥20% FB in Timed 25-foot Walk Test (T25FWT) score OR 3)12-week CI of ≥ 20% FB in 9-hole Peg Test (9-HPT) score. EDSS = disability scale that ranges in 0.5-point steps from 0 \[normal\]-10.0 \[death\]. In T25FWT test participants walked to a 25 foot course as quickly \& safely as possible. Score = average of 2 completed trials (in seconds). In 9-HPT, participants had to place \& remove pegs 1 by 1 into 9 holes arranged in a board \& complete 2 successful trials for each hand \& the amount of time (in seconds) required was recorded. In T25FWT \& 9-HPT the longer it took complete test= higher scores, indicating deterioration.

Time frame:
Up to approximately 4.5 years
Reported as:
Median · weeks
Time to Onset of 12-week Composite Confirmed Disability Progression (cCDP12)
weeksOcrelizumab 600 mgOcrelizumab 1200 mg or 1800 mg
Time to Onset of 12-week Composite Confirmed Disability Progression (cCDP12)158.7 (120.0 to NA)169.0 (144.1 to NA)
Statistical analysis
  • Ocrelizumab 600 mg vs Ocrelizumab 1200 mg or 1800 mg · Log Rank · p = 0.6376 · Hazard ratio (hr): 0.95 · 95% CI 0.76 to 1.18
SecondaryTime to Onset of 24-week cCDP (cCDP24)

Time to onset of a 24 week cCDP=first occurrence of a 24-week cCDP according to at least 1 of 3 criteria: 1) CDP=24-week CI from baseline in EDSS score of ≥1.0 point in participants with baseline EDSS score of ≤5.5 or 24-week CI≥0.5 point in participants with baseline EDSS score of \>5.5 OR 2) 24-week CI of ≥20% FB in T25FWT score OR 3) 24-week CI of ≥ 20% FB in 9-HPT score. EDSS = disability scale that ranges in 0.5-point steps from 0 \[normal\]-10.0 \[death\]. In T25FWT test participants walked to a 25 foot course as quickly \& safely as possible. Score = average of 2 completed trials (in seconds). In 9-HPT, participants had to place \& remove pegs 1 by 1 into 9 holes arranged in a board \& complete 2 successful trials for each hand \& the amount of time (in seconds) required was recorded. In T25FWT \& 9-HPT the longer it took complete test= higher scores, indicating deterioration.

Time frame:
Up to approximately 4.5 years
Reported as:
Median · weeks
Time to Onset of 24-week cCDP (cCDP24)
weeksOcrelizumab 600 mgOcrelizumab 1200 mg or 1800 mg
Time to Onset of 24-week cCDP (cCDP24)NA (144.1 to NA)NA (180.1 to NA)
Statistical analysis
  • Ocrelizumab 600 mg vs Ocrelizumab 1200 mg or 1800 mg · Log Rank · p = 0.4148 · Hazard ratio (hr): 0.91 · 95% CI 0.72 to 1.15
SecondaryTime to Onset of cCDP12 Independent of Protocol-defined Relapses (PDR) or Progression Independent of Relapse Activity (PIRA)

Time to onset of 12-week cCDP=first occurrence of a 12-week cCDP according to at least 1 of 3 criteria: 1) CDP=12-week CI from baseline in EDSS score of ≥1.0 point in participants with baseline EDSS score of ≤5.5 or 12-week CI≥0.5 point in participants with baseline EDSS score of \>5.5 OR 2) 12-week CI of ≥20% FB in T25FWT score OR 3) 12-week CI of ≥ 20% FB in 9-HPT score. EDSS score, T25FWT \& 9-HPT are the same as defined in primary outcome measure. Protocol-defined relapse=occurrence of new or worsening neurological symptoms attributable to MS and immediately preceded by a relatively stable or improving neurological state of at least 30 days. Symptoms persist for at least 24 hours \& accompanied by objective neurological worsening consistent with an increase of one of the following: Half a step (0.5 point) on the EDSS; Two points on one of the functional system scores (FSS) (pyramidal, ambulation, cerebellar, brainstem, sensory, or visual); One point on ≥2 more of the FSS.

Time frame:
Up to approximately 4.5 years
Reported as:
Median · weeks
Time to Onset of cCDP12 Independent of Protocol-defined Relapses (PDR) or Progression Independent of Relapse Activity (PIRA)
weeksOcrelizumab 600 mgOcrelizumab 1200 mg or 1800 mg
Time to Onset of cCDP12 Independent of Protocol-defined Relapses (PDR) or Progression Independent of Relapse Activity (PIRA)183.0 (120.1 to NA)180.1 (145.0 to NA)
Statistical analysis
  • Ocrelizumab 600 mg vs Ocrelizumab 1200 mg or 1800 mg · Log Rank · p = 0.5764 · Hazard ratio (hr): 0.94 · 95% CI 0.75 to 1.17
SecondaryTime to Onset of 12-week Confirmed Disability Progression (CDP12)

CDP was defined as a 12-week confirmed increase from baseline in EDSS score of ≥1.0 point in participants with a baseline EDSS score of ≤5.5 or a 12-week CI ≥0.5 points in participants with a baseline EDSS score of \>5.5. The EDSS was used to measure changes in the disability level of participants with MS over time. EDSS is based on a standard neurological examination, incorporating functional systems (visual, brainstem, pyramidal, cerebellar, sensory, bowel and bladder, and cerebral \[or mental\]) that are rated and then scored as a FSS, and ambulation, which is scored as ambulation score. Each FSS is an ordinal clinical rating scale where score range from 0 to 5 or 6, and ambulation score that is rated from 0 to 16. These ratings along with observations and assistive devices were then used to determine the total EDSS score. The total EDSS score ranges from 0 (normal) to 10.0 (death) in 0.5-point steps.

Time frame:
Up to approximately 4.5 years
Reported as:
Median · weeks
Time to Onset of 12-week Confirmed Disability Progression (CDP12)
weeksOcrelizumab 600 mgOcrelizumab 1200 mg or 1800 mg
Time to Onset of 12-week Confirmed Disability Progression (CDP12)NA (NA to NA)NA (214.1 to NA)
Statistical analysis
  • Ocrelizumab 600 mg vs Ocrelizumab 1200 mg or 1800 mg · Log Rank · p = 0.3223 · Hazard ratio (hr): 0.86 · 95% CI 0.65 to 1.15
SecondaryTime to ≥ 20% Increase in 12-week Confirmed T25FWT

T25FWT test is a performance measure used to assess walking speed based on a timed 25-foot walk. The participant was directed to start at one end of a clearly marked 25-foot course and was instructed to walk 25 feet as quickly and safely as possible. The Examining Investigator timed the participants from the start of the walk to the end of the 25 feet. The task was immediately administered again by having the participant walk back the same distance. Participants could use assistive devices (e.g., cane, crutch, or rollator) when performing the task. Score was the average of the two completed trials, measured in seconds. The longer it takes to walk, higher the score, indicating deterioration. A 20% change from baseline of the averaged T25FWT was considered clinically meaningful.

Time frame:
Up to approximately 4.5 years
Reported as:
Median · weeks
Time to ≥ 20% Increase in 12-week Confirmed T25FWT
weeksOcrelizumab 600 mgOcrelizumab 1200 mg or 1800 mg
Time to ≥ 20% Increase in 12-week Confirmed T25FWT216.1 (173.0 to NA)NA (192.4 to NA)
Statistical analysis
  • Ocrelizumab 600 mg vs Ocrelizumab 1200 mg or 1800 mg · Log Rank · p = 0.5478 · Hazard ratio (hr): 0.93 · 95% CI 0.73 to 1.18
SecondaryTime to Onset of 12-week Confirmed ≥ 4-point Worsening in Symbol Digit Modalities Test (SDMT)

The SDMT is a performance measure that demonstrated sensitivity in detecting the presence of cognitive impairment and changes in cognitive functioning over time \& in response to treatment. The SDMT presents a series of nine symbols, each paired with a single digit in a key at the top of a standard sheet of paper. Participants were asked to pair specific numbers with given geometric figures within 90 seconds. Responses were collected orally. The score is the number of correctly paired items in 90 seconds with a maximum score of 110 and minimum of 0. Higher scores indicate improvement. A four-point change from baseline was considered clinically meaningful.

Time frame:
Up to approximately 4.5 years
Reported as:
Median · weeks
Time to Onset of 12-week Confirmed ≥ 4-point Worsening in Symbol Digit Modalities Test (SDMT)
weeksOcrelizumab 600 mgOcrelizumab 1200 mg or 1800 mg
Time to Onset of 12-week Confirmed ≥ 4-point Worsening in Symbol Digit Modalities Test (SDMT)NA (NA to NA)226.1 (NA to NA)
Statistical analysis
  • Ocrelizumab 600 mg vs Ocrelizumab 1200 mg or 1800 mg · Log Rank · p = 0.6495 · Hazard ratio (hr): 0.92 · 95% CI 0.64 to 1.32
SecondaryTime to Onset of 24-week Confirmed ≥ 8-point Increase in 12-Item Multiple Sclerosis Walking Scale (MSWS-12)

The MSWS-12 was a 12-item self-report measure of the impact of MS on the participant's ability to walk during the past 2 weeks. Each item was scored on a 5-point Likert scale ranging from 1 (not at all) to 5 (extremely likely). Scores were summed and linearly converted to a 0-100 scale with higher scores indicating greater impact of MS on walking ability. An 8-point change was considered clinically meaningful.

Time frame:
Up to approximately 4.5 years
Reported as:
Median · weeks
Time to Onset of 24-week Confirmed ≥ 8-point Increase in 12-Item Multiple Sclerosis Walking Scale (MSWS-12)
weeksOcrelizumab 600 mgOcrelizumab 1200 mg or 1800 mg
Time to Onset of 24-week Confirmed ≥ 8-point Increase in 12-Item Multiple Sclerosis Walking Scale (MSWS-12)NA (146.0 to NA)168.6 (146.0 to NA)
Statistical analysis
  • Ocrelizumab 600 mg vs Ocrelizumab 1200 mg or 1800 mg · Log Rank · p = 0.1281 · Hazard ratio (hr): 1.22 · 95% CI 0.94 to 1.59
SecondaryAnnual Rate of Percent Change From Baseline in Total Brain Volume

Brain volume was measured using magnetic resonance imaging (MRI) scans. Mean difference in annual rate of percent change from baseline in total brain volume between the higher and approved dose of ocrelizumab arms in participants with RMS where no treatment discontinuation nor initiation of alternative MS treatment occurred, are reported.

Time frame:
Up to approximately 4.5 years
Reported as:
Mean · percent change per year
Annual Rate of Percent Change From Baseline in Total Brain Volume
percent change per yearOcrelizumab 600 mgOcrelizumab 1200 mg or 1800 mg
Annual Rate of Percent Change From Baseline in Total Brain Volume-0.480 ± 0.048-0.548 ± 0.044
Statistical analysis
  • Ocrelizumab 600 mg vs Ocrelizumab 1200 mg or 1800 mg · Wald Test · p = 0.0802 · Difference in annual rates of change: -0.069 · 95% CI -0.145 to 0.008
SecondaryAnnual Rate of Percent Change From Baseline in Thalamic Volume

Thalamic volume was measured using MRI scans. Mean difference in annual rate of percent change from baseline in thalamic volume between the higher and approved dose of ocrelizumab arms in participants with RMS where no treatment discontinuation nor initiation of alternative MS treatment occurred, are reported.

Time frame:
Up to approximately 4.5 years
Reported as:
Mean · percent change per year
Annual Rate of Percent Change From Baseline in Thalamic Volume
percent change per yearOcrelizumab 600 mgOcrelizumab 1200 mg or 1800 mg
Annual Rate of Percent Change From Baseline in Thalamic Volume-0.974 ± 0.096-1.006 ± 0.087
Statistical analysis
  • Ocrelizumab 600 mg vs Ocrelizumab 1200 mg or 1800 mg · Wald Test · p = 0.7021 · Difference in annual rates of change: -0.032 · 95% CI -0.198 to 0.133
SecondaryRatio of Fold Change From Baseline in Neurofilament Light Chain (NfL) Levels at Week 96

NfL is a biomarker of neuroinflammation in CSF. Ratio of the mean change from baseline in NfL at Week 96 between the higher and approved dose of ocrelizumab arms in PPMS participants where no treatment discontinuation nor initiation of alternative MS treatment occurred have been reported. The results correspond to fold change from baseline (i.e., ratio of adjusted geometric means at Week 96 vs baseline).

Time frame:
At Week 96
Reported as:
Mean · ratio
Ratio of Fold Change From Baseline in Neurofilament Light Chain (NfL) Levels at Week 96
ratioOcrelizumab 600 mgOcrelizumab 1200 mg or 1800 mg
Ratio of Fold Change From Baseline in Neurofilament Light Chain (NfL) Levels at Week 960.78 (0.74 to 0.82)0.82 (0.79 to 0.85)
Statistical analysis
  • Ocrelizumab 600 mg vs Ocrelizumab 1200 mg or 1800 mg · Wald Test · p = 0.1126 · Ratio of fold changes: 1.05 · 95% CI 0.99 to 1.12
SecondaryFold Change From Baseline in NfL Levels at Week 96 Within the Higher Dose Ocrelizumab Group

NfL is a biomarker of neuroinflammation in CSF. Mean change from baseline in NfL at Week 96 for PPMS participants where no treatment discontinuation nor initiation of alternative MS treatment occurred within the ocrelizumab higher dose group have been reported. The results correspond to fold change from baseline (i.e., ratio of adjusted geometric mean at Week 96 vs baseline).

Time frame:
At Week 96
Reported as:
Mean · ratio
Fold Change From Baseline in NfL Levels at Week 96 Within the Higher Dose Ocrelizumab Group
ratioOcrelizumab 1200 mg or 1800 mg
Fold Change From Baseline in NfL Levels at Week 96 Within the Higher Dose Ocrelizumab Group0.82 (0.79 to 0.85)
SecondaryFold Change From Baseline in NfL Levels at Week 96 Within the Approved Dose Ocrelizumab Group

NfL is a biomarker of neuroinflammation in CSF. Mean change from baseline in NfL at Week 96 for PPMS participants where no treatment discontinuation nor initiation of alternative MS treatment occurred within the ocrelizumab 600 mg group have been reported. The results correspond to fold change from baseline (i.e., ratio of adjusted geometric mean at Week 96 vs baseline).

Time frame:
At Week 96
Reported as:
Mean · ratio
Fold Change From Baseline in NfL Levels at Week 96 Within the Approved Dose Ocrelizumab Group
ratioOcrelizumab 600 mg
Fold Change From Baseline in NfL Levels at Week 96 Within the Approved Dose Ocrelizumab Group0.78 (0.74 to 0.82)
SecondaryNumber of Participants With Adverse Events (AEs)

AE was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

Time frame:
From initiation of study drug up to approximately 6.8 years

Results for this outcome have not been posted.

SecondaryArea Under the Serum Concentration-time Curve (AUC) of Ocrelizumab Over the First Dosing Interval
Time frame:
Day 1 to Week 24
Reported as:
Geometric mean · micrograms/milliliter*day (µg/mL*day)
Area Under the Serum Concentration-time Curve (AUC) of Ocrelizumab Over the First Dosing Interval
micrograms/milliliter*day (µg/mL*day)Ocrelizumab 600 mgOcrelizumab 1200 mg or 1800 mg
600 mg2740 ± 0.37—
1200 mg—6410 ± 0.202
1800 mg—7100 ± 0.269
SecondaryB-cell Levels in Blood
Time frame:
Baseline, Weeks 2, 24, 48, 72, 96, 120, 144, 168, 192 and 216
Reported as:
Mean · cells/microliters (cells/μL)
B-cell Levels in Blood
cells/microliters (cells/μL)Ocrelizumab 600 mgOcrelizumab 1200 mg or 1800 mg
Baseline260.23 ± 177.83249.25 ± 135.00
Week 25.95 ± 34.213.75 ± 25.71
Week 2412.47 ± 36.535.77 ± 16.90
Week 4812.49 ± 39.927.58 ± 26.88
Week 7213.81 ± 45.569.58 ± 78.06
Week 968.55 ± 31.876.29 ± 39.04
Week 1207.76 ± 28.5010.37 ± 93.01
Week 1449.38 ± 41.264.66 ± 21.56
Week 1684.40 ± 18.269.07 ± 71.97
Week 1924.47 ± 17.754.60 ± 33.04
Week 2163.43 ± 7.970.73 ± 0.83
SecondaryPercent Change From Baseline in B-cell Levels
Time frame:
Weeks 2, 24, 48, 72, 96, 120, 144, 168, 192 and 216
Reported as:
Mean · percent change
Percent Change From Baseline in B-cell Levels
percent changeOcrelizumab 600 mgOcrelizumab 1200 mg or 1800 mg
Change at Week 2-97.66 ± 11.25-97.55 ± 23.32
Change at Week 24-94.62 ± 18.44-96.85 ± 11.87
Change at Week 48-95.19 ± 12.21-94.51 ± 34.39
Change at Week 72-93.54 ± 23.55-93.88 ± 61.26
Change at Week 96-96.53 ± 13.83-94.89 ± 45.13
Change at Week 120-97.07 ± 9.20-93.55 ± 67.99
Change at Week 144-97.31 ± 7.93-97.72 ± 11.81
Change at Week 168-97.62 ± 11.47-94.29 ± 54.94
Change at Week 192-97.95 ± 9.02-98.40 ± 9.90
Change at Week 216-98.24 ± 4.33-99.73 ± 0.32
SecondaryPercentage of Participants Who Achieved ≤ 5 B-cells/μL of Blood
Time frame:
Baseline, Weeks 2, 24, 48, 72, 96, 120, 144, 168, 192 and 216
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved ≤ 5 B-cells/μL of Blood
percentage of participantsOcrelizumab 600 mgOcrelizumab 1200 mg or 1800 mg
Baseline00.4
Week 296.195.8
Week 2468.481.2
Week 4875.782.5
Week 7278.487.3
Week 9680.489.1
Week 12082.890.8
Week 14485.593.5
Week 16886.893.1
Week 19288.196.6
Week 21690.9100
SecondaryPercentage of Participants Who Achieved ≤ 0.4 B-cells/μL of Blood
Time frame:
Baseline, Weeks 2, 24, 48, 72, 96, 120, 144, 168, 192 and 216
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved ≤ 0.4 B-cells/μL of Blood
percentage of participantsOcrelizumab 600 mgOcrelizumab 1200 mg or 1800 mg
Baseline00.2
Week 223.830.2
Week 245.79.4
Week 488.612.4
Week 7212.318.2
Week 9616.830.4
Week 12020.030.8
Week 14423.941.4
Week 16834.941.7
Week 19245.246.1
Week 21627.363.6
SecondaryPercentage of Participants With Anti-drug Antibodies (ADAs) to Ocrelizumab

Participants were considered to be ADA-positive if they were ADA-negative or had missing data at baseline but developed an ADA response following study drug exposure, or if they were ADA-positive at baseline and the titer of 1 or more post-baseline samples was at least 0.60 titer unit (t.u.) greater than the baseline titer result. Percentages have been rounded off.

Time frame:
Up to approximately 4.5 years
Reported as:
Number · percentage of participants
Percentage of Participants With Anti-drug Antibodies (ADAs) to Ocrelizumab
percentage of participantsOcrelizumab 600 mgOcrelizumab 1200 mg or 1800 mg
Percentage of Participants With Anti-drug Antibodies (ADAs) to Ocrelizumab1.60.8

Adverse events

Collected over From initiation of study drug up to approximately 4.5 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ocrelizumab 600 mg3/254 (1.2%)29/254 (11.4%)176/254 (69.3%)
Ocrelizumab 1200 mg or 1800 mg2/499 (0.4%)61/499 (12.2%)381/499 (76.4%)
Most frequent serious events
Showing 10 of 105
Most frequent serious events
EventOcrelizumab 600 mgOcrelizumab 1200 mg or 1800 mg
COVID-19 pneumoniaInfections and infestations3/2542/499
Urinary tract infectionInfections and infestations2/2545/499
COVID-19Infections and infestations1/2544/499
PneumoniaInfections and infestations2/2543/499
AgranulocytosisBlood and lymphatic system disorders0/2542/499
ConstipationGastrointestinal disorders0/2542/499
SepsisInfections and infestations0/2542/499
Femur fractureInjury, poisoning and procedural complications0/2542/499
Infusion related reactionInjury, poisoning and procedural complications0/2542/499
HyperkalaemiaMetabolism and nutrition disorders0/2542/499
Most frequent other events
Showing 10 of 15
Most frequent other events
EventOcrelizumab 600 mgOcrelizumab 1200 mg or 1800 mg
Infusion related reactionInjury, poisoning and procedural complications59/254118/499
COVID-19Infections and infestations45/25481/499
NasopharyngitisInfections and infestations40/25484/499
Urinary tract infectionInfections and infestations26/25481/499
Upper respiratory tract infectionInfections and infestations27/25476/499
HeadacheNervous system disorders36/25465/499
Back painMusculoskeletal and connective tissue disorders19/25451/499
FallInjury, poisoning and procedural complications19/25447/499
Respiratory tract infectionInfections and infestations18/25413/499
ArthralgiaMusculoskeletal and connective tissue disorders18/25433/499

Baseline characteristics

Full analysis set (FAS) included all randomized participants, with participants grouped according to the treatment they were assigned.

Age, Continuous
Age, Continuous(years)Ocrelizumab 600 mgOcrelizumab 1200 mg or 1800 mgTotal
Mean41.7 ± 8.941.8 ± 9.141.8 ± 9.0
Sex: Female, Male
Sex: Female, Male(Participants)Ocrelizumab 600 mgOcrelizumab 1200 mg or 1800 mgTotal
Female133266399
Male120234354
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Ocrelizumab 600 mgOcrelizumab 1200 mg or 1800 mgTotal
American Indian or Alaska Native92433
Asian134
Native Hawaiian or Other Pacific Islander000
Black or African American141024
White215444659
More than one race347
Unknown or Not Reported111526
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Ocrelizumab 600 mgOcrelizumab 1200 mg or 1800 mgTotal
Hispanic or Latino3477111
Not Hispanic or Latino207404611
Unknown or Not Reported347
Not Permitted91524
09

Study locations

147 sites

Showing the first 100 of 147 sites across 22 countries. Choose a country and city above to see the rest.

10

References and documents

Publications

  • Hauser SL, Giovannoni G, Montalban X, Oh J, Bar-Or A, Sormani MP, Weber MS, Stoll S, Nicholas JA, Nehrych T, Bonek R, Selmaj K, Maciejowski M, Zecevic D, Raposo C, Owen R, Bonati U, Madjar K, Harfst E, Wang Q, Raievska A, Manfrini M, Schneble HM, Kappos L; MUSETTE and GAVOTTE Study Groups. Efficacy and safety of a bodyweight-adjusted higher dose of ocrelizumab in relapsing (MUSETTE) and primary progressive (GAVOTTE) multiple sclerosis: two multicentre, randomised, double-blind, parallel-group phase 3b trials. Lancet. 2026 May 30;407(10544):2180-2194. doi: 10.1016/S0140-6736(26)00147-9. PubMed 42208560 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2020 to primary completion in Jun 2025, 54 months.

Results were first posted in Jul 2026, 1 year after primary completion.

Of 20 phase 3 interventional studies under Multiple Sclerosis, Chronic Progressive, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 52 and three quarters within 83. This study's 54 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2020
First posted
Sep 16, 2020
StartActual
Dec 3, 2020
Primary completionActual
Jun 30, 2025
CompletionEst.
Sep 8, 2027
Results first posted
Jul 24, 2026
Last update
Jul 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT04548999
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Sep 16, 2020
Start date
Dec 3, 2020
Primary completion
Jun 30, 2025
Completion
Sep 8, 2027 (estimated)
Results posted
Jul 24, 2026
Last update
Jul 24, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ocrelizumab

Start the discussion